Borosil Scientific Q1 FY26: Decoding the Loss – Is There a Hidden Opportunity?

Borosil Scientific Limited has just unveiled its Q1 FY26 earnings, and if you just glanced at the headline numbers, you might be excused for a sharp intake of breath. The company reported a consolidated net sales decline and, quite starkly, a consolidated PAT loss. But as seasoned investors know, the devil, or rather the opportunity, is often in the details. Let’s peel back the layers to understand what truly shaped Borosil Scientific’s performance this quarter and what it signals for the road ahead.

A Challenging Start to FY26: The Headline Numbers

At first blush, Borosil Scientific’s consolidated financial performance for Q1 FY26 appears to have taken a significant hit compared to the same period last year.

Yes, you read that right: consolidated net sales dipped by 8.2%, and the company swung to a consolidated PAT loss of ₹4.2 crores from a profit of ₹5.0 crores last year. EBITDA margins also compressed notably. However, these figures don’t tell the full story. There were some significant one-off items that materially skewed the profitability.

Deciphering the Profitability Puzzle: More Than Meets the Eye

Before we delve deeper into sales, it’s crucial to understand the major factors impacting earnings. Borosil Scientific highlighted two key items that heavily influenced its Q1 FY26 profitability:

1. IND AS 115 Accounting Impact: A non-cash accounting adjustment of ₹2.59 crores due to IND AS 115 affected EBITDA.
2. Voluntary Retirement Scheme (VRS) Expense: The company incurred a substantial one-time expense of ₹6.61 crores related to a VRS at its Ambad plant. This is classified as an exceptional item.

Let’s do a quick back-of-the-envelope calculation. The total impact of these two items is approximately ₹9.2 crores (₹2.59 Cr + ₹6.61 Cr). If we were to adjust the reported consolidated PAT of -₹4.2 crores for these one-time and accounting items, the adjusted PAT would be closer to a positive ₹5.0 crores.

What does this tell us? 🤔 It suggests that operationally, the company’s profitability, while pressured by lower sales, was not nearly as dismal as the headline PAT loss implies. The significant dip in earnings is largely attributable to these specific, non-recurring factors. This is a critical distinction for investors looking for underlying trends rather than one-off hits.

Sales Performance: A Mixed Bag with Pockets of Growth

While the overall sales figure declined, a segment-wise breakdown reveals a nuanced picture.

Key Observations:

• Scientific Segment: This segment, the largest, saw a 10.4% decline.
  • Lab Consumables: A 9.3% decline, primarily due to a significant drop in export sales. Geopolitical uncertainties and U.S. import tariffs played spoilsport here. The company stated domestic sales were robust, indicating a demand shift. Given the broader market trend of export-linked sectors underperforming, this isn’t surprising.
  • Process System: The steepest decline at 31.4%. This was attributed to a lower opening order book and delays in execution with key customers, pushing orders into Q3 FY26. This signals a revenue deferral rather than a complete loss of business.
  • Lab Equipments: A bright spot, growing 12.4% YoY! 🎉 This segment’s growth is encouraging, especially since it’s typically a higher-margin business for the company.
• Glassware Segment: A modest 3.0% decline.
  • Pharma Packaging: A marginal but positive 2.0% growth. This stability in a critical segment (serving the pharmaceutical industry, their largest customer base) is a positive indicator.
  • Domestic Glassware: Declined by 8.3%.

Overall, the sales performance was challenged by external factors (export tariffs) and internal factors (deferred orders in Process Systems). However, the resilience of Lab Equipments and Pharma Packaging, alongside healthy domestic Lab Consumables sales, offers some comfort.

Order Book Insights: Process Systems Gears Up for Future Growth 📈

For a B2B focused segment like Process Systems, the order book is a forward-looking indicator. While Q1 FY26 sales for this segment suffered due to a low opening order book and deferred execution, there’s a promising twist:

• “Fresh order bookings in Q1 FY26 were substantially higher than the previous year, supported by new product development, customer base expansion, talent strengthening, and operational efficiency improvements aimed at boosting future sales and profitability.”

This is crucial. It suggests that while Q1 was impacted by past order dynamics, the current quarter’s order intake has been robust, pointing to potential revenue recovery and growth in subsequent quarters, particularly Q3 FY26, when these deferred orders are expected to be executed. This aligns with management’s focus on expanding this higher-margin segment.

Working Capital and Financing: A Positive Shift in Liquidity

The company’s net debt position showed a remarkable improvement. From being in a net debt position of ₹2.6 crores in Q1 FY25, Borosil Scientific moved to a net cash position of ₹116.8 crores in Q1 FY26 (consolidated). This significant shift towards a stronger liquidity position is a huge positive, indicating effective cash management or healthy cash inflows during the period. It provides a strong financial cushion for future growth initiatives.

Capital Expenditure (CapEx) & Future Growth Plans

While specific CapEx figures for Q1 FY26 weren’t detailed, the investor presentation highlighted ongoing strategic investments:

• A 450 kW Solar rooftop project commissioned in Feb 2025, demonstrating commitment to sustainability and cost efficiency.
• The company’s medium-term goals include strategically expanding LabQuest (Lab Equipment) and Process Sciences to broaden product ranges and achieve a 12-14% revenue CAGR. This implies continued investment in these high-growth, high-margin areas.
• The acquisition of Goel Scientific has already enhanced expertise in Chemical Process Systems.

The focus on high-margin segments for growth suggests a calculated approach to future CapEx, aimed at enhancing profitability and market share.

Investment Insight: A Company in Transition, Aspiring for Fast Growth

Borosil Scientific Limited appears to be a company in a transition phase. While Q1 FY26 presented a challenging picture with revenue decline and a headline PAT loss, the underlying reasons (one-time VRS expense, accounting adjustment, and deferred orders) suggest that the operational core might be more resilient than initial numbers indicate.

The company’s ambition to achieve a 12-14% revenue CAGR and improve EBITDA margins, coupled with the strong new order bookings in Process Systems and the positive shift to a net cash position, points towards an aspiration to be a fast grower. However, current performance, especially the reliance on export markets for Lab Consumables (which are facing headwinds in the broader Indian economy context), positions it more as a slow grower or even a turnaround story for now.

Key Takeaways for Investors:

• Don’t Judge a Book by Its Cover: The Q1 FY26 PAT loss is largely due to one-time/accounting adjustments. Focus on the adjusted profitability for a clearer operational view.
• Order Book is Key: The higher fresh order bookings for Process Systems in Q1 FY26, despite deferred execution, provide a strong indicator for revenue recovery in Q3 FY26 and beyond. This segment’s performance will be critical.
• Diversification & Domestic Focus: The strength in domestic Lab Consumables and Lab Equipments underscores the importance of a domestic growth theme, aligning with broader market preferences in India. Continued focus on ‘Make in India’ and domestic market penetration is crucial.
• Liquidity Strength: The substantial shift to a net cash position provides financial flexibility and stability, which is a significant positive amidst revenue pressures.
• Monitor Execution: Management’s medium-term goals are ambitious. The real test will be their ability to convert the strong order book into sales and improve margins as guided.

Borosil Scientific’s Q1 FY26 results were undoubtedly tough, but a deeper dive reveals a story of temporary headwinds and strategic positioning for future growth. Investors should closely monitor the execution of deferred orders and the company’s progress on its margin improvement initiatives in the coming quarters.

Join our Telegram for instant updates!